IDMC Recommends Continuation of IMNN-001 Phase 2 MRD Study After Favorable Safety Review
IMNN is trading near its 52-week low of $1.33 (7.5% above the low).
Summary
An independent data monitoring committee has recommended that Imunon's Phase 2 MRD study of IMNN-001 continue without modification after reviewing all safety data to date. The committee found no new safety signals and confirmed comparable safety across both treatment arms. This is the first independent safety validation for the study, which is evaluating IMNN-001 in combination with bevacizumab and in the maintenance setting for newly diagnosed advanced ovarian cancer. The recommendation follows encouraging preliminary MRD data reported in July showing lower MRD positivity and higher ctDNA clearance. The safety profile is a key differentiator for this IL-12-based immunotherapy, and the IDMC's endorsement supports the ongoing pivotal Phase 3 OVATION 3 trial. Investors will look for further efficacy data from the MRD study and enrollment progress in OVATION 3.
At the time of this announcement, IMNN was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $1.33 to $5.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.